Evaluation of the Effect of Sildenafil Nutrition on the Treatment of Injection Routine (Milirinone) in Infants with Pulmonary Hypertension

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190731044393N1

Enrollment

Registered

2019-10-04

Start date

2019-09-01

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary hypertension. Primary pulmonary hypertension

Interventions

Intervention 1: Intervention group: In the intervention group sildenafil (3 mg / kg / day) is given with milrinone. Intervention 2: Control group: In control group only injectable milrinone is prescr

Eligibility

Sex/Gender

All

Age

1 Days to 28 Days

Inclusion criteria

Inclusion criteria: Infants hospitalized in neonatal wards of Afzalipour Hospital Parental Satisfaction Gestational age greater than or equal to 34 weeks Confirmation of diagnosis of high blood pressure by echocardiography

Exclusion criteria

Exclusion criteria: Congenital heart disease The birth of a major anomaly

Design outcomes

Primary

Measure	Time frame
Evidence of pulmonary hypertension. Timepoint: The first day and 72 hours later. Method of measurement: Eco cardiography.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Ebrahimpour

Kerman University of Medical Sciences

maryamebrahimpour@gmail.com+98 34 3132 8000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026